Arena shares slip after report on serious adverse event in PAH study; Zealand partners with Eli Lilly;

@FierceBiotech: Popular yesterday: Gilead's sofosbuvir cures some of the toughest hepatitis C cases. Article | Follow @FierceBiotech

@JohnCFierce: Strange story: Low-profile Epirus lays claim to a PhIII success for Remicade biosimilar--backed by TPG, 5AM. News | Follow @JohnCFierce

@RyanMFierce: GoogleVentures bets on oral biologics from startup Rani Therapeutics. Report | Follow @RyanMFierce

@EmilyMFierce: Worm genome reveals possible drug targets. Item from FierceBiotech Research | Follow @EmilyMFierce

> Arena Pharmaceuticals ($ARNA) had a slight amendment to make to a recent 8-K filing. In a follow-up document, the troubled biotech noted that there had been a serious adverse event in its Phase I study of an experimental PAH drug. The amended filing also notes that investigators say that it is possible the event, a transient case of atrial fibrillation, is linked to the drug. The safety concerns took a 4% bite out of Arena's share price this morning. Filing

> Denmark's Zealand Pharma has forged an exclusive peptide drug research and development collaboration agreement with Eli Lilly ($LLY). The pact covers new drugs for Type 2 diabetes and obesity. Release

> San Francisco-based Nektar Therapeutics ($NKTR) is in line for a $25 million milestone payment in the event that the EMA accepts AstraZeneca's ($AZN) application for naloxegol. Story

Medical Device News

@FierceMedDev: Sign up to receive our new publication FierceDiagnostics in your inbox each Wednesday. Sign up here | Follow @FierceMedDev

@DamianFierce: St. Jude won a CE mark for its next-gen renal denervation device. News | Follow @DamianFierce

@MarkHFierce: There's a new brain cancer MRI Dx approach, and Harvard Medical School is partially behind it. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: Chip lined with human cells tests cancer drug delivery with minimal cost. FierceDrugDelivery article | Follow @MichaelGFierce

> Biotronik boosts MRI-safe options for pacemaker tech. Story

> LipoScience back to drawing board after FDA rebuff. Report

> HeartWare expands heart pump trial for destination therapy. More

Pharma News

@FiercePharma: Trending on our website: Top 20 orphan drugs by 2018. Special Report | Follow @FiercePharma

@CarlyHFierce: China's Simcere going private thanks to $495M buyout by chairman. ICYMI yesterday Follow @CarlyHFierce

> Novartis discount fails to persuade NICE on Afinitor in breast cancer. Article

> Bayer's Eylea challenges Novartis eye drug for share of new market. Report

Vaccines News

> Novartis begins shipping flu vaccines ahead of crucial season. Article

> Analysis finds most vaccines safe during breastfeeding. Report

> International Vaccine Institute inks Indian alliances. Item

> Herd immunity from GSK, Merck vaccines cutting hospitalizations. Story

> Low vaccination rate at megachurch linked to measles outbreak. Report

Pharma Manufacturing News

@EricPFierce: India's GRAF building nutraceutical plant. It sees the category as source of future revenue growth. Article | Follow @EricPFierce

> Injectable drugs to drive CMO growth. Story

> Fast-growing ICIG adds peptide manufacturer. Article

> Novartis OTC unit has another foul-up. Report

> DOJ files suit against plant with persistent issues. More

And Finally… New insights on hearing loss have inspired some fresh thinking on drugs that could prevent damage. Release